Venus Concept's Pain Management Device Scores FDA Nod

The FDA has given 510(k) clearance to Venus Concept Inc's VERO Venus Freedom device for pain management.
Venus Freedom is a noninvasive, non-ablative device with three applicators to deliver non-thermal radiofrequency energy combined with massage and magnetic field pulses.
It is intended for minor muscle aches & pain, relief of muscle spasms, and temporary improvement of local blood circulation.
Related: Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook.
The Company will commence a limited launch of Venus Freedom in the U.S. during Q1 of 2022.
Price Action: VERO shares are up 2.50% at $2.05 during the market session on the last check Tuesday.

Momentum6.71

Growth14.65

Quality-

Value38.33

Short

Medium

Long